WO2023012475 - ENGINEERING OF GAMMA DELTA T CELLS AND COMPOSITIONS THEREOF
National phase entry:
Publication Number
WO/2023/012475
Publication Date
09.02.2023
International Application No.
PCT/GB2022/052039
International Filing Date
03.08.2022
Title **
[English]
ENGINEERING OF GAMMA DELTA T CELLS AND COMPOSITIONS THEREOF
[French]
INGÉNIERIE DE LYMPHOCYTES T GAMMA DELTA ET COMPOSITIONS ASSOCIÉES
Applicants **
GAMMADELTA THERAPEUTICS LTD
Inventors
KOVACS, Istvan
Priority Data
63/228,972
03.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5053 | |
| EPO | Filing, Examination, Granting | 113904 | |
| Japan | Filing, Examination, Granting | 4880 | |
| South Korea | Filing, Examination, Granting | 8512 | |
| USA | Filing, Examination, Granting | 28140 |
Total:
160,489
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention provides methods of engineering γδ T cells (e.g., vδ1 T cells and vδ2 T cells) by transduction with a viral vector (e.g., a viral vector with a betaretroviral pseudotype and a 5 Retroviridae family viral vector backbone). Further provided are compositions of engineered γδ T cells and methods of using the same.[French]
La présente invention concerne des procédés d'ingénierie des lymphocytes T γδ (par exemple, les lymphocytes T vδ1 et les lymphocytes T vδ2) par transduction avec un vecteur viral (par exemple, un vecteur viral à pseudotype bêtarétroviral et une chaîne principale de vecteur viral de la famille 5 Retroviridae). La présente invention concerne également des compositions de lymphocytes T γδ modifiées et des procédés d'utilisation de celles-ci.